Skip to Content

Viatris Inc

VTRS: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$94.00MxzxNtzrgsmr

Viatris Raises Guidance Following Strong Second Quarter

Viatris announced strong second-quarter results across all segments, driven by increased demand for COVID-19-related generic products and steady growth in biosimilars. Management raised full-year revenue guidance to $17.5–17.9 billion, up from $17.2–17.8 billion, and raised adjusted EBITDA guidance to $6.15–6.45 billion, up from $6.0–6.4 billion. The company also paid its first dividend of $0.11 per share this quarter. We maintain our fair value estimate of $25 per share on no-moat Viatris.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of VTRS so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center